Physician profile
Frank Lopez
NPI 1497759039
$4,893.80
in general payments reported to CMS, 2019-2025
29 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $650 · 2021: $704 · 2022: $1,078 · 2023: $996 · 2024: $329 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,727.49 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.56 | 2019-2023 | Entyvio |
| Pfizer INC. | $337.77 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.29 | 2019-2023 | Xifaxan, Plenvu |
| Genzyme Corporation | $268.26 | 2022-2025 | |
| Janssen Biotech, INC. | $262.21 | 2019-2023 | Remicade, Stelara, Simponi Aria |
| Celgene Corporation | $214.01 | 2021-2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $207.87 | 2022-2025 | Lesionhunter |
| Regeneron Healthcare Solutions, INC. | $134.73 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $114.94 | 2020-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $112.29 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $104.71 | 2019-2025 | |
| Intra-Sana Laboratories | $74.11 | 2021-2022 | |
| Ucb, INC. | $67.76 | 2019 | |
| Lilly USA, LLC | $65.97 | 2024 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $64.55 | 2023 | Sucraid |
| Ardelyx, INC. | $62.23 | 2023-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $61.39 | 2022 | |
| Braintree Laboratories, INC. | $60.08 | 2019-2023 | Sutab |
| Daiichi Sankyo INC. | $45.98 | 2019-2022 | |
| Organon LLC | $29.41 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $28.14 | 2022 | |
| Shionogi INC | $27.18 | 2019 | |
| Dentsply Ih Ab | $20.76 | 2024 | Lofric |
| Amgen INC. | $17.23 | 2020 | |
| Olympus America INC. | $15.58 | 2019 | |
| Boston Scientific Corporation | $13.53 | 2025 | Watchman Flx |
| Amag Pharmaceuticals, INC. | $12.94 | 2019 | |
| Allergan, INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.